FDA Approves Treatment for Glucocorticoid-Induced Osteoporosis

Officials with the FDA have approved the use of denosumab (Prolia, Amgen) for the treatment of glucocorticoid-induced osteoporosis (GIOP).

Officials with the FDA have approved the use of denosumab (Prolia, Amgen) for the treatment of glucocorticoid-induced osteoporosis (GIOP), according to a press release.

The treatment is indicated for men and women at high risk of fracture, defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available therapies.

The approval is based on data from 12-month analysis of a 24-month phase 3 trial evaluating the safety and efficacy of denosumab. According to the findings, patients on glucocorticoid therapy who received denosumab had greater gains in bone mineral density (BMD) compared with those who received active comparator risedronate.

Denosumab 60 mg was administered subcutaneously every 6 months compared with oral risedronate 5 mg once daily in 795 patients receiving glucocorticoid treatment, greater than or equal to 7.5 mg/day oral prednisone, or equivalent, according to the study.

Click to continue reading on Specialty Pharmacy Times.